AbbVie (ABBV) Cash from Investing Activities (2012 - 2026)

AbbVie (ABBV) has reported Cash from Investing Activities for 15 consecutive years, with -$574.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 21.9% year-over-year to -$574.0 million; the TTM figure through Mar 2026 stood at -$6.5 billion (up 45.83% YoY), while the FY2025 annual figure was -$6.6 billion, up 68.09% from the prior year.
• Cash from Investing Activities grew to -$574.0 million in Q1 2026 per ABBV's latest filing, from -$1.5 billion in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $1.3 billion in Q3 2022 and bottomed at -$9.6 billion in Q1 2024.
• Historically, Cash from Investing Activities has averaged -$1.8 billion across 5 years, with a median of -$800.0 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 309.11% — and 2024, when it slumped 2137.4%.
• AbbVie's Cash from Investing Activities stood at -$448.0 million in 2022, then plunged by 78.57% to -$800.0 million in 2023, then slumped by 134.25% to -$1.9 billion in 2024, then rose by 21.93% to -$1.5 billion in 2025, then jumped by 60.77% to -$574.0 million in 2026.
• Business Quant data shows ABBV's Cash from Investing Activities at -$574.0 million in Q1 2026, -$1.5 billion in Q4 2025, and -$3.3 billion in Q3 2025.